Arcturus Therapeutics In... (ARCT)
| Bid | 12 |
| Market Cap | 350.12M |
| Revenue (ttm) | 138.39M |
| Net Income (ttm) | -80.94M |
| EPS (ttm) | -3 |
| PE Ratio (ttm) | -4.3 |
| Forward PE | -3.3 |
| Analyst | Buy |
| Ask | 13.66 |
| Volume | 226,796 |
| Avg. Volume (20D) | 438,356 |
| Open | 12.51 |
| Previous Close | 12.89 |
| Day's Range | 12.45 - 12.98 |
| 52-Week Range | 8.04 - 45.00 |
| Beta | 3.41 |
About ARCT
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as we...
Analyst Forecast
According to 6 analyst ratings, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 364.76% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call TranscriptArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne...
